FDA: Evalua decisiones sobre "legal cannabis & CBD"

 As cannabis becomes legalized in an increasing number of states – New York State is set to open its first legal recreational marijuana dispensary Thursday – the Food and Drug Administration is weighing how it will regulate the substance as well as cannabis-derived CBD.

Ver:

First licensed retail cannabis dispensary opens in NY

The agency plans to make recommendations on how to regulate CBD, or cannabidiol, in food and supplements in the coming months.

While CBD doesn’t cause the “high” that tetrahydrocannabinol, or THC, does, products containing it are still not technically FDA-approved, aside from Epidiolex, a CBD treatment for rare seizure disorders.

Ver:

Todo sobre Epidiolex en PHARMACOSERÍAS

In 2018, Congress removed hemp (and thus hemp-derived CBD) from the federal Controlled Substances Act, leaving it to states to decide whether to allow the sale of CBD products.

As of now, the FDA has dictated that CBD can’t be added to foods or marketed as supplements, and companies must provide evidence from clinical trials if they claim their CBD products are therapeutic. Aside from that, however, companies selling CBD products haven’t had specific federal rules on how to market their products.

The agency is thus preparing to develop clearer ones after investigating whether CBD can be considered a food or supplement as opposed to simply a drug.

In an interview with The Wall Street Journal this week, FDA principal deputy commissioner Janet Woodcock, MD noted that CBD “raises concerns for FDA about whether these existing regulatory pathways for food and dietary supplements are appropriate for this substance.”

In particular, the FDA wants to examine whether CBD can be ingested every day and over long-term periods safely, and whether it’s safe during pregnancy. They’re also aiming to better educate consumers on the wide variety of CBD products that are already out there – all of which have different levels of quality and safety.

“The safety profiles around these products are not what they are generally accustomed to and not the same as what they get from other products when they walk into a wellness store or grocery store or even a gas station,” Norman Birenbaum, a senior adviser at the FDA, told The Wall Street Journal.

Still, the CBD and cannabis-derived products industry has expanded in recent years, expected to grow from a $4.6 billion market in 2021 to nearly four times that by 2026.

The National Cannabis Industry Association, a trade group for cannabis businesses, has argued that any federal guidelines should fall into place with current state guidelines that allow the sale of CBD.

“The states are decades ahead of the federal government,” Aaron Smith, CEO of the trade group, told The Wall Street Journal. Medical marketers, meanwhile, have long jumped on the opportunity to begin exploring how to market legal cannabis brands as more states allow the sale of it.

Citario : Pan, iris y CBD / Isabel Coixet

 

 

"El tercer misterio es la proliferación de tiendas de CBD, (el cannabis sin de tiendarahidrocannabinol), que es la parte psicoactiva de la marihuana (para entendernos, la que coloca): no hay barrio que se precie que no tenga dos o doscientas. En crema, aceite, capsulas, píldoras, gominolas, espray o cargadores para vapear, el CBD parece la panacea para todos los males, físicos y mentales. Igual yo debo de poseer algún gen raro o ser inmune al CBD, porque confieso que, habiendo probado todas esas cosas, con más o menos intensidades, no he sentido ni tan siquiera un ligero alivio. 

Me pregunto si estos negocios, las panaderías chachis, las tiendas de fotografías de iris y los negocios de CBD, tienen futuro o irán a compartir limbo con los lugares donde mataban a los piojos o enseñaban a hacer macramé." 

Isabel Coixet

Ver también...:

 Todo sobre CBD en PHARMACOSERIAS

 

 

Y ahora...Cannabidiol (CBD) and Ibuprofen Formulation to Treat Pain

Stevia Corp., an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of a second important provisional patent application with the United States Patent and Trademark Office for the treatment of pain using ibuprofen and Cannabidiol (CBD).

 The provisional patent application closely follows the company’s previously announced first provisional patent application for pain comprising acetaminophen and CBD. As in the previously filed application, this patent includes multiple claims including but not limited to combinations of cannabinoids including CBD and ibuprofen for the treatment of pain.

The provisional patent application was filed with the assistance of an intellectual property attorney with extensive experience in the healthcare industry. A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming “first to file” status against other companies or individuals that may want to file a patent with similar claims after the filing date of our provisional patent.(...)

Cannabidiol (CBD) is a cannabinoid that is present in most varieties of the cannabis sativa and cannabis indica plants. Cannabinoids are unique to the cannabis sativa and cannabis indica plants. Unlike some of the other molecules found in varieties of the cannabis plant, it is non-psychoactive and it is not believed to have any addictive properties. It is also extremely well tolerated at high doses with little or no side effects. Cannabidiol catapulted into a national story after being an important part of the 2013 CNN documentary “Weed”.




George Blankenbaker, Stevia Corp commented, “This is our second key provisional patent application related to pain which is one of the largest healthcare markets in the world. In the past two weeks, we have announced our intention to secure patents and to launch products that contain specific cannabinoids in combination with either ibuprofen or acetaminophen. Ibuprofen and acetaminophen are two of the largest selling OTC drugs in the world and are the key ingredients behind Motrin® and Tylenol®.” (Más)

Ver:
Todo sobre Cannabis en PHARMACOSERÍAS

Para_Pharma_Lia: MedChew RX / AXIM

.

.

La marihuana contiene más de 100 cannabinoides, pero los más populares y útiles médicamente son el cannabidiol (CBD) y el tetrahidrocannabinol (THC) .

La nueva patente permite a AXIM “garantizar la entrega de todos los cannabinoides” sintéticos y naturales y, entre ellos el THC, aunque sin provocar un efecto psicoactivo.

Este medicamento en forma de goma de mascar o chicle sólo estará disponible para el mercado farmacéutico. En otras palabras, sólo se podrá obtener recetado por un médico.

AXIM no es ajeno al mercado de la goma de mascar con marihuana. La compañía ha ganado su notoriedad después del debut de su primer producto similar el CanChew. Para la producción de los cristales de CBD se utilizó un nivel de pureza del 99,9%.

El nuevo producto MedChew RX incluye el CBD y el THC , y está siendo probado en ensayos clínicos. Se espera que el producto medicinal se utilice para el tratamiento del dolor y para la reducción de los espasmos musculares en pacientes con esclerosis múltiple, problemas reumáticos como artritis, artrosis y fibromialgia entre otras dolencias.

La compañía espera que la tercera fase de los ensayos clínicos se completen en el tercer o cuarto trimestre del 2017 y luego será presentado para su aprobación a la Administración de Alimentos y Medicamentos y a la Agencia Europea de Medicamentos.

Se espera que el MedChew RX sea registrado en el 2018.
“No todos los chicles o goma de mascar con THC son lo mismo. Hay muchos otros productos en el mercado, pero no contienen cannabinoides puros y sin ningún tipo de contaminación “. AXIM utiliza su propio método de extracción para obtener el THC puro de alta calidad. Este proceso también ayudará a vender el producto aproximadamente en un 20% más barato que el actual CanChew, que se vende por $ 56 el paquete de 33 chicles; mientras baja el precio yo uso una crema calmante de cannabis. (Ver)

Ver también:

Humor...es lunes:HandzOff/Medica_mentalización del "amor propio"...no es paja.

Para_pharma_lia: Chicles Stevia / Ufff...

Chicles de "salud"...

Para_Pharma_Lia: Foria vaginal

.

Marijuana is becoming increasingly recognized as an effective medicinal product by both the common public and medical professionals alike. 

Ver:
Todo sobre marihuana/cannabis en PHARMACOSERÍAS

It is known to be able to treat a variety of medical conditions, ranging from glaucoma to insomnia. However, it is probably best known for its use as a painkiller. Marijuana is used to relieve many different types of pain, including pain caused by chemotherapy, inflammatory diseases and injuries. 
Thanks to a new invention developed by Foria, a company focused on producing innovative cannabis products, marijuana’s pain killing properties may mean the end of period cramps as well.

Ver:

Para_Pharma_Lia: Foria*

Cannabis Tampons 

Although the product being sold by Foria, called Foria Relief, aren’t typically considered to be tampons, they are suppositories that are inserted in a similar fashion. They can even be used along with tampons to maximize their comforting effects. 
The suppositories are made out of only three natural ingredients: organic cocoa butter, THC oil, and CBD isolate. 
According to Foria, the combination of both THC oil and CBD isolate is meant to “activate certain cannabinoid receptors in the pelvic region when introduced into the body.” 
 This effect reportedly causes a decrease in pain and discomfort that often accompanies menstruation, and many users of the product have backed this claim up. The cannabinoids found in the suppositories causes the nerves in the uterus, cervix and ovaries to block out pain. It also relaxes any of the surrounding smooth muscle tissue to further increase comfort during menstruation.

Ver también:
Aunt Flo, Meet Mary J! Pot Suppository Supposedly Cures Cramps

How To Use It  

Foria Relief is meant to relieve pain closest to the area where it is inserted. This means it can be inserted vaginally to relieve pain in the womb area often caused by menstruation. 
Some users have also reported benefits from inserting it rectally, claiming that it relieved pain in the back and hip area, places which are also commonly affected by menstruation. On average, women reported feeling pain and comfort relief around 15-30 minutes after insertion. If being used in combination with a typical tampon, Foria Relief should be inserted prior to the tampon. (Más)

.

.

España: Epidyolex primer medicamento a base de cannabis

 

 

 

 

 

Eva S. Corada @evacorada 

 

Ya es una realidad: el primer medicamento exclusivamente a base de cannabidiol (CBD) -sustancia química extraída del cannabis- aprobado ya está disponible en nuestro país. Aunque, eso sí, será dispensado en a través de la farmacia hospitalaria para su uso como tratamiento -junto con clobazam- de la epilepsia. En concreto para las crisis asociadas al síndrome de Lennox-Gastaut (SLG) y al síndrome de Dravet (SD) en pacientes a partir de dos años de edad.

Epidyolex -que es cómo se llama el fármaco- es una solución oral que contiene cannabidiol (CBD) altamente purificado. En septiembre de 2019 recibió la aprobación de la Comisión Europea, lo que le convirtió en el primer medicamento de prescripción a base de cannabis derivado de plantas en recibir esta autorización. La aprobación de cannabidiol solución oral se basó en los resultados de cuatro ensayos de fase III controlados y aleatorizados conn datos de más de 714 pacientes con ambas patologías. España ha participado en el desarrollo clínico de esta terapia con más de diez hospitales.

“El acceso a un nuevo medicamento con un mecanismo de acción novedoso y clínicamente probado es un motivo de esperanza para los pacientes y de satisfacción para los especialistas que vemos a menudo pacientes con epilepsias altamente resistentes”, afirma Antonio Gil-Nagel Rein, neurólogo y director del Programa de Epilepsia del Hospital Ruber Internacional de Madrid, quien señala que “la potencial mejora de la calidad de vida en un área donde las opciones terapéuticas son muy pequeñas es una buena noticia”.

../...

Pero ¿cómo funciona? Tal y como explica el director médico del Área de Epilepsia de Jazz Pharmaceuticals en España, Ángel Ayuga, este medicamento “utiliza un mecanismo de acción novedoso ya que reduce la hiperexcitabilidad neuronal y la inflamación a través de la modulación del calcio intracelular y de los neurotransmisores en la neurona presináptica”.

Los síndromes de Lennox-Gastaut (SLG) y Dravet (SD) son dos formas raras de epilepsia con elevados índices de morbilidad y mortalidad, y que suponen una importante carga para las familias y los cuidadores. Muchos pacientes con SLG o SD tienen múltiples crisis epilépticas cada día, lo que les coloca en riesgo constante de sufrir caídas y lesiones. A pesar del actual tratamiento con medicamentos antiepilépticos, estas dos graves formas de epilepsia son muy resistentes al tratamiento.

Más

Ver: Cannabinoides en PHARMACOSERÍAS

NICE: SATIVEX ok en MS

The National Institute for Health and Care Excellence (NICE) has recommended Bayer’s Sativex (delta-9 tetrahydrocannabinol (THC) cannabidiol (CBD)), for spasticity in people with multiple sclerosis (MS).

Ver:

SATIVEX: Esplendor en la "yerba" para Bayer

The cannabis-based medicinal product has been approved within its licensed indication, as the organisation deemed it clinically and cost effective at its current list price. NICE also updated the MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder.

The news follows a previous positive health technology appraisal of the treatment in spasticity by the All Wales Medicines Strategy Group (AWMSG).

Sativex, developed by GW Pharma and marketed in the UK by Bayer, has been approved for use in the United Kingdom since June 2010 for the treatment of some symptom improvement in adult patients with moderate to severe spasticity due to MS.

Ver también:

Sativex: Cuestión de pr_incipios?...No, de pr_ecios.

The new guideline has been hailed as “very positive for people living with moderate to severe MS spasticity who are not responding to their current medication.”

Dr Jackie Napier, medical director, neurology at Bayer explained that the company “looks forward to the rapid implementation of this guideline to broaden the range of treatment options currently available.”

It is estimated that MS affects 100,000 people in the UK with spasticity a common symptom and major contributor to disability. Spasticity can range from mild muscle stiffness to severe, painful and uncontrollable muscle spasms, and as a consequence an individual may have difficulty in walking, picking up objects, washing, dressing and other everyday activities involving movement. Ver

Ver:
Todo sobre SATIVEX en `PHARMACOSERÍAS

CBD "sobreexpuesto"

 

España: Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs: Spain (I)

Cannabinoid Drugs

For the purposes of this topic shall mean any industrially produced medicinal product which contains cannabinoids.

1. Are Cannabinoid Drugs authorized in your country?

Cannabinoid Drugs may be authorized in Spain on the basis of scientific criteria on its quality, safety and efficacy. The foregoing is provided that applicable regulations on narcotics, such as Law 17/1967 on narcotics, and Royal Decree 2829/1977 on narcotics and its production, distribution, prescription and dispensation are observed.

2. What are the regulatory authorities with jurisdiction over Cannabinoid Drugs?

The main Spanish authorities with jurisdiction over Cannabinoid Drugs are the Spanish Ministry of Health and the AEMPS.

3. Is there a specific regulatory framework for the authorization, pricing, and reimbursement of Cannabinoid Drugs?

No. The general regulatory framework applicable for the authorization, pricing and reimbursement of medicinal products apply to Cannabinoid Drugs.

There are, however, specific regulations that may be applicable to other activities related to Cannabinoid Drugs such as manufacturing, distributing, prescribing, dispensing etc. (see, among others, Law 17/1967, Royal Decree 2829/1977 and Royal Decree 1675/2012 on prescribing and dispensing narcotics for both human and veterinary use).

4. Which are the cannabinoid drugs that have received market approval to date?

To date, only Sativex 2,7 mg / 2,5 mg Oromucosal spray solution (“Sativex®”) has received market approval in Spain. Sativex® is a Cannabinoid Drug which contains, per each single 100 microlitre spray, 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) from Cannabis sativa L. 
The marketing authorization holder of Sativex is GW Pharma Ltd. 

Ver:
Todo sobre GW Pharma en PHARMACOSERÍAS

Sativex® has been classified as a hospital diagnosis drug, which means that it shall only be used for the treatment of diseases diagnosed either in hospitals or centers which have appropriate diagnosis means, or by specialized doctors (see art. 24.3.b of Royal Decree 1345/2007 on the procedure for authorization of industrially produced medicinal products for human use).

Likewise, according to section 4.1 of the technical sheet of Sativex®, Sativex® must only be used “to improve symptoms of adult patients with moderated or serious spasticity due to multiple sclerosis” if “other anti-spasticity medicines have not worked” and “a significant clinical improvement has been observed regarding the symptoms of spasticity after an initial trial period of the treatment”.

5. Who can prescribe Cannabinoid Drugs?

Doctors, odontologists and veterinaries, each of them in the field of its competence, can prescribe narcotic drugs.

6. Is there a list of doctors authorized to prescribe Cannabinoid Drugs?

There is not a list of doctors authorized to prescribe Cannabinoid Drugs. Doctors, provided that they comply with the applicable requirements and procedures (which include the need to use the appropriate prescription forms), can prescribe Cannabinoid Drugs without need to be previously registered in any official list. It is to be noted that doctors holding prescription forms for narcotic drugs may be controlled (and, therefore, somehow listed) but these are lists relating to the prescription forms (holders of such forms are listed) and not related to the doctors themselves.

7. What approvals or notifications are required to prescribe Cannabinoid Drugs?

Provided that applicable regulations are complied with (including the use of the appropriate prescription forms), doctors themselves do not have to ask for any specific approval or make any specific notification each time they prescribe Cannabinoid Drugs.

8. Which organizations are authorized to sell/distribute Cannabinoid Drugs available?

Cannabinoid Drugs can be dispensed to the public by authorized pharmacy offices/services.

Cannabinoid Drugs can be distributed (that is, sold to either other authorized distribution entities or pharmacy offices/services) by any of the following entities provided that they comply with all applicable regulations on medicinal products and narcotics (such as Law 17/1967, Royal Decree 2829/1977 -and its complementary regulations- and Royal Decree 1675/2012):

Pharmaceutical laboratories; Distribution entities duly authorized to distribute medicines for human use (see Royal Decree 782/2013 on distribution of medicinal products for human use); and/or Distribution entities duly authorized to distribute veterinary medicines (see Royal Decree 109/1995 on veterinary medicinal products).

9. Is there a list of retailers/distributors authorized to sell Cannabinoid Drugs?

Retailers. The AEMPS, with the cooperation of the regional authorities, publishes lists including all pharmacy offices opened to the public in Spain. Such pharmacy offices can dispense Cannabinoid Drugs if they comply with applicable regulations (please refer to Question 8). Distributors. 
The AEMPS publishes lists including all entities authorized to distribute veterinary medicines and medicines for human use in Spain. All entities authorized to distribute Cannabinoid Drugs must be included in such lists.

10. Are there proposals for reform or significant change to the regulation of Cannabinoid Drugs?

We are not aware of any proposal to significantly reform the regulation of Cannabinoid Drugs in Spain.

11. When are they likely to come into force?

N/A

Cannabinoid drugs, medicinal cannabis and opioid drugs in Spain – a legal guide. 
Prepared in association with Faus & Moliner Abogados, a leading law firm in Spain, this is an extract from 
The Pharma Legal Handbook: Spain

SATIVEX: Esplendor en la "yerba" para Bayer

"Aunque mis ojos ya no puedan ver ese puro destello, que me deslumbraba.
Aunque ya nada pueda devolver la hora del esplendor en la hierba de la gloria en las flores, no hay que afligirse.
Porque la belleza siempre subsiste en el recuerdo....."

William Wordsworth

Era el "leitmotiv" en la "peli" de Kazan que "removió" nuestra adolescencia...
Natalie Wood...! (Natalia ponian los afiches en España por eso del "doblaje total"). Warren Beatty...!
Ufff...

Ahora es Bayer quien se lleva la "yerba" (no me sale escribirlo con dos l´s") al agua con SATIVEX.

Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK.

Sativex treats the spasticity symptoms of multiple sclerosis, such as spasms and cramps, and is manufactured with government permission at a secret UK location.

It is the first cannabinoid medicine to be derived from whole plant extracts of the cannabis sativa plant and contain both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Professor John Zajicek, a neurology consultant at Derriford Hospital in Plymouth, said Sativex’s launch was a milestone for cannabinoid medicines.

“Current standard therapy for MS-associated spasticity can produce side effects which patients may find difficult to cope with and not all of them are specifically licensed for spasticity.

“Sativex on the other hand has mainly mild to moderate side effects, which can be easily controlled by adjusting the dose. It has really benefited those people who have found it effective and is a useful addition to available treatments.”

Mas

SATIVEX con patente en USA

GW Pharmaceuticals.plc announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent which protects the use of Sativex as a treatment for cancer pain.

The patent, entitled “Pharmaceutical Compositions for the Treatment of Pain”, provides an exclusivity period until April 2025. The patent specifically covers a method of treating cancer related pain by administering a combination of the cannabinoids cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC), the two principal cannabinoids in Sativex. In addition to this newly granted patent, Sativex is protected by a number of other patents related to different aspects of the product.

Sativex is currently in phase III clinical development as a treatment for cancer pain. Cancer pain represents the lead indication for Sativex in the United States, where the medicine is partnered with Otsuka Pharmaceutical Co. Ltd.

Dr Geoffrey Guy, GW’s chairman, said, “The grant of this US patent covering Sativex as a treatment for cancer pain is part of a broad platform of intellectual property rights which continue to be developed by GW. GW now has 35 patent families as well as other forms of protection such as plant variety rights and proprietary know-how. We believe that this matrix of intellectual property provides GW with a unique position to benefit from the rich promise within the field of cannabinoid therapeutics.”

Sativex is approved in the UK, Spain, Czech Republic, Canada and New Zealand as a treatment of Multiple Sclerosis spasticity. (Más)

SATIVEX: Autorizado en España

USA Marijuana: A Changing Legal and Research Environment

Marijuana: A Changing Legal and Research Environment   

Although this Report does not examine the issue of marijuana legalization, its continually evolving legal status is worth mentioning because of implications for both research and policy. As mentioned elsewhere, marijuana is the most commonly used illicit drug in the United States, with 22.2 million people aged 12 or older using it in the past month.3 In recent years marijuana use has become more socially acceptable among both adults and youth, while perceptions of risk among adolescents of the drug’s harms have been declining over the past 13 years.

As use of marijuana and its constituent components and derivatives becomes more widely accepted, it is critical to strengthen understanding of the effects and consequences for individual users and for public health and safety. 

Ver:

Millennials y drogas...

Conducting such research can be complex as laws and policies vary significantly from state to state. For example, some states use a decriminalization model, which means production and sale of marijuana are still illegal and no legal marijuana farms, distributors, companies, stores, or advertising are permitted. Through ballot initiatives, other states have “legalized” marijuana use, which means they allow the production and sales of marijuana for personal use. Additionally, some states have legalized marijuana for medical purposes, and this group includes a wide variety of different models dictating how therapeutic marijuana is dispensed. The impacts of state laws regarding therapeutic and recreational marijuana are still being evaluated, although the differences make comparisons between states challenging.

Ver:

USA: Trump & "Pot"...triumph

As of June 2016, 25 states and the District of Columbia have legalized medical marijuana use. Four states have legalized retail sales; the District of Columbia has legalized personal use and home cultivation (both medical and recreational), with more states expecting to do so. None of the permitted uses under state laws alters the status of marijuana and its constituent compounds as illicit drugs under Schedule I of the federal Controlled Substances Act.93 It should also be noted that use for recreational purposes has not been legalized by any jurisdiction for people under age 21, and few jurisdictions have legalized medical marijuana for young people. While laws are changing, so too is the drug itself with average potency more than doubling over the past decade (1998 to 2008).94 The ways marijuana is used are also changing – in addition to smoking, consuming edible forms like baked goods and candies, using vaporizing devices, and using high-potency extracts and oils (e.g., “dabbing”) are becoming increasingly common.95 Because these products and methods are unregulated even in states that have legalized marijuana use, users may not have accurate information about dosage or potency, which can lead and has led to serious consequences such as hospitalizations for psychosis and other overdose-related symptoms.95 Marijuana use can also impair driving skills and, while estimates vary, is linked to a roughly two-fold increase in accident risk.96-98 The risk is compounded when marijuana is used with alcohol.96,99 

There is a growing body of research suggesting the potential therapeutic value of marijuana’s constituent cannabinoid chemicals in numerous health conditions including pain, nausea, epilepsy, obesity, wasting disease, addiction, autoimmune disorders, and other conditions.

Ver:

Potencial terapéutico del cannabis y los cannabinoides.

Given the possibilities around therapeutic use, it is necessary to continue to explore ways of easing existing barriers to research. Marijuana has more than 100 constituent cannabinoid compounds, with cannabidiol (CBD) and tetrahydrocannabinol (THC, the chemical responsible for most of marijuana’s intoxicating effects) being the most well-studied. Evidence collected so far in clinical investigations of the marijuana plant is still insufficient to meet PAGE | 1-22 FDA standards for a finding of safety and efficacy for any therapeutic indications.

However, the FDA has approved three medications containing synthetically derived cannabinoids: Marinol capsules and Syndros oral solution (both containing dronabinol, which is identical in chemical structure to THC), and Cesamet capsules (containing nabilone, which is similar in structure to THC) for severe nausea and wasting in certain circumstances, for instance in AIDS patients.

Ver.
FDA Approves Syndros, Marijuana In Liquid Form — But Is It More Effective Than Pills? 

Medical Marijuana...gran negocio.

Recognizing the potential therapeutic importance of compounds found in marijuana, the FDA has granted Fast Track designation to four development programs of products that contain marijuana constituents or their synthetic equivalents. The therapeutic areas in which products are being developed granted Fast Track by FDA include the treatment of pain in patients with advanced cancer; treatment of Dravet syndrome (two programs), a rare and catastrophic treatment-resistant form of childhood epilepsy; and treatment of neonatal hypoxic ischemic encephalopathy, brain injury resulting from oxygen deprivation during birth. 

Additionally, there are clinical investigations for the treatment of refractory seizure syndromes, including Lennox Gastaut Syndrome, and for treatment of post-traumatic stress disorder (PTSD). However, further exploration of these issues always requires consideration of the serious health and safety risks associated with marijuana use. Research shows that risks can include respiratory illnesses, dependence, mental health-related problems, and other issues affecting public health such as impaired driving. Within this context of changing marijuana policies at the state level, research is needed on the impact of different models of legalization and how to minimize harm based on what has been learned from legal substances subject to misuse, such as alcohol and tobacco. Continued assessment of barriers to research and surveillance will help build the best scientific foundation to support good public policy while also protecting the public health. (Más)

Ver también:

La marihuana sale del armario / Mario Vargas Llosa

Creatividad: Parafernalia botánica CBD

 

Visto en CPhI 2016 Barcelona (III): En Suiza también se cultiva cannabis...Linnea.

Y se "promociona"...

Cannabis
Cannabis sativa L. extract (THC< 0.1%)

Linnea extracts and manufactures Cannabis as a botanical ingredient for pharmaceutical purposes. 

A growing number of clinical studies indicates that Cannabis and its phytocannabinoids may have a relevant medicinal value for certain diseases. The mechanisms of action of the single cannabinoids and their interaction in biological human system are also becoming increasingly clear.

Ver cannabis en PHARMACOSERÍAS

The discovery of the endocannabinoid system and its physiological functions contribute to understanding a significant potential role of Cannabis in medicine. 

CBD or cannabidiol, is one of the major non-psychotropic cannabinoid found in Cannabis. It has shown antiepileptic, anti-inflammatory, anti-emetic, muscle relaxing, anxiolytic, neuroprotective and anti-psychotic-like activity and reduces the psychoactive effects of THC (tetrahydrocannabinol).

Linnea Cannabis Extract is obtained exclusively from the inflorescence of female plants, from a selected clone of Cannabis for its specific cannabinoids profile. 

Plants are cultivated in accordance to strict procedures that guarantee GAP application and compliance to national regulation.

Cultivation are done in Switzerland in greenhouses or in the field. In order to assure the quality of Cannabis through the cultivation process, Linnea staff is present on site to monitor all procedures involved in planting, harvesting, cleaning, storing and transporting.

Ver anteriores Visto en CPhI 2016 Barcelona

Mary´s Cannabis transdermal patch

"We (Mary´s) make transdermal cannabis products and cannabis supplements. Today we're talking a lot about our patches -- it's the first transdermal cannabis product that is cleanly delivered and medical-grade. You can put it on your wrist and it lasts 8-12 hours. It also comes in six different varieties -- indica, sativa, hybrid and then isolated cannabinoids like CBD and CBN. We also have a few other products like gels and CBC compounds that are good to supplement your patch. 

What's the science behind that patch? 

The patch itself works similar to a nicotine patch. It delivers the cannabis straight into your bloodstream, which is the most efficient way to medicate. You avoid all of the side-effects of smoking or eating it. When you're putting it into your bloodstream, it is much more efficient. So one 10mg patch is equivalent to maybe an 80mg edible. Most of the THC is going into your bloodstream instead of being broken down by your stomach acid. It's the most efficient way to medicate.(Más)

MEXICO: Ex Presidente Fox KOL para KHIRON.

.

After participating in CannaMexico 2018, a prominent medical cannabis conference hosted by Centro Fox, it was clear that the collaboration between Khiron, former President Fox and Centro Fox provided the opportunity to greatly advance our shared interests in increasing the level of education and understanding of the benefits of medical cannabis for all of Latin America.

His appointment to our board also significantly expands our scope of influence and relationships within the Latin American market.

Appointment expands business and political network and furthers development of medical cannabis education and research across Latin America

TORONTO, July 17, 2018 /CNW/ – 

Khiron Life Sciences Corp., a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that the Company has appointed former President of Mexico Mr. Vicente Fox Quesada to its board of directors, effective immediately. Mr. Fox will be a strategic advisor and brand ambassador for the Company, furthering the Company’s education and brand leadership interests across Latin America. 
From December 2000 to November 2006, Mr. Fox was the 55th President of Mexico. Prior to that, he was the Chief Executive Officer of Coca Cola Latin America.

Mr. Fox is the Founder of Centro Fox, a nonprofit foundation dedicated to serving communities in Mexico and Latin America. Through his various business and community interests, Mr. Fox has been a high profile and respected advocate for the legalization of medical cannabis throughout the Latin American region. He currently serves on the board of directors of a leading US based cannabis publication advocating legalization.

Further, this appointment puts us in a strong position to expedite our expansion plans to other strategic markets, keeping with our goal of becoming the dominant regional medical cannabis company in Latin America. On behalf of the board of directors and Khiron team, I welcome former President Fox to Khiron.

As previously announced, Khiron is strategically positioned to enter the Mexican market, establishing a subsidiary in the country to submit license applications, completing an in-depth regulatory review of the country’s legal medical cannabis landscape as well as an assessment of market needs. Mexico comprises a population of approximately 123.5 million people, with nearly 11.7 million potential patients for medical cannabis.

To Centro Fox and President Fox this represents a great opportunity to accomplish our dream of reducing violence in Mexico due to the underground and illegal crime activities related to Cannabis and move to a new legal industry creating jobs and income for families, taxes to governments and wealth creation, as well as innovative and creative actions to strengthen citizens and families’ health.

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. 
In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. (Más)